Creo Medical Group (LON:CREO) Announces Quarterly Earnings Results

Key Points

• Creo Medical Group reported earnings of GBX 4 per share for the quarter, with a notable negative return on equity of 41.79% and a negative net margin of 73.93%.
• The company's stock opened at GBX 12.13, and it has a market cap of £50.05 million, with a P/E ratio of -151.68.
• Insider transactions included the sale of 12,858 shares by two insiders, each at an average price of GBX 14, totaling around £1,800.

Creo Medical Group (LON:CREO - Get Free Report) released its quarterly earnings results on Monday. The company reported GBX 4 earnings per share for the quarter, Digital Look Earnings reports. Creo Medical Group had a negative return on equity of 41.79% and a negative net margin of 73.93%.

Creo Medical Group Stock Performance

CREO stock traded down GBX 0.28 during trading hours on Monday, reaching GBX 11.85. The stock had a trading volume of 1,795,061 shares, compared to its average volume of 1,065,302. The stock has a 50-day simple moving average of GBX 13.08 and a 200 day simple moving average of GBX 12.58. Creo Medical Group has a fifty-two week low of GBX 9.22 and a fifty-two week high of GBX 28.50. The stock has a market capitalization of £48.88 million, a PE ratio of -148.13 and a beta of 0.86. The company has a debt-to-equity ratio of 29.96, a current ratio of 3.24 and a quick ratio of 2.19.

Insider Activity

In other Creo Medical Group news, insider Craig Jonathan Gulliford sold 6,429 shares of the company's stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of GBX 14, for a total value of £900.06. Also, insider Richard John Rees sold 6,429 shares of the stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of GBX 14, for a total transaction of £900.06. Company insiders own 4.10% of the company's stock.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.